SpringWorks Therapeutics, Inc.
SWTX
$37.06
-$0.86-2.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1,029.96% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,029.96% | -- | -- | -- | -- |
| Cost of Revenue | 1,216.11% | -- | -- | -- | -- |
| Gross Profit | 1,014.33% | -- | -- | -- | -- |
| SG&A Expenses | 28.85% | 32.34% | 23.08% | 36.08% | 47.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.51% | 27.67% | 26.31% | 47.93% | 32.45% |
| Operating Income | 17.39% | 31.03% | 45.78% | -20.89% | -25.50% |
| Income Before Tax | 18.05% | 32.61% | 48.77% | -19.02% | -27.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.05% | 32.61% | 48.77% | -19.02% | -27.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.05% | 32.61% | 48.77% | -19.02% | -27.16% |
| EBIT | 17.39% | 31.03% | 45.78% | -20.89% | -25.50% |
| EBITDA | 17.97% | 31.67% | 46.55% | -20.34% | -25.23% |
| EPS Basic | 28.01% | 43.27% | 56.83% | -0.56% | -21.18% |
| Normalized Basic EPS | 28.01% | 43.27% | 56.83% | -0.57% | -21.20% |
| EPS Diluted | 28.01% | 43.27% | 56.83% | -0.56% | -21.18% |
| Normalized Diluted EPS | 28.01% | 43.27% | 56.83% | -0.57% | -21.20% |
| Average Basic Shares Outstanding | 13.83% | 18.78% | 18.66% | 18.36% | 4.93% |
| Average Diluted Shares Outstanding | 13.83% | 18.78% | 18.66% | 18.36% | 4.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |